Parke, Davis & Company v. Doctor's Pharmaceuticals, Inc.
REITERATIONFacts
The Antecedents: This case stemmed from a prior decision (G.R. No. L-22221) where the Supreme Court affirmed the Director of Patents' order for petitioner Parke Davis & Company to grant respondent Doctor's Pharmaceuticals, Inc. a license to manufacture, use, and sell its products containing petitioner's chemical "chloramphenicol" under Letters Patent No. 50. Procedural History: Following the finality of the decision in G.R. No. L-22221 and the parties' failure to submit a licensing agreement, the Director of Patents, on March 25, 1966, and amended on November 25, 1966, issued a license fixing the terms and conditions. This license stipulated an 8% royalty rate on net sales, which petitioner deemed grossly inadequate, proposing a 15% rate. The Petition: Petitioner argued that the 8% royalty rate was arbitrary and unsupported by evidence, citing higher prevailing rates (15-18%) in other compulsory licenses for medicines and citing international examples. Respondent countered with lower rates from other licensing agreements. Petitioner also questioned the Director's authority to declare the resolution immediately executory.
Issue(s)
Whether the Director of Patents committed a grave abuse of discretion in fixing the royalty rate at 8%. Whether the Director of Patents has the authority to declare his resolution immediately executory.
Ruling
The petition is dismissed, and the resolution of the Director of Patents is affirmed in all respects.
Ratio Decidendi
On the issue of the royalty rate: The Court held that findings of fact by administrative bodies, such as the Director of Patents, will not be interfered with by courts unless there is a grave abuse of discretion or the findings are not supported by substantial evidence. In this case, the Director of Patents made a compromise between the petitioner's proposed rate and rates prevailing in other countries, considering the context of developing countries and the relative size of the local industry. The 8% rate was deemed reasonable, being midway between rates cited from Canada and Norway. The Court agreed with the Solicitor General that there was no showing of business losses for petitioner or adverse effects on the saleability of the antibiotic or public health due to the 8% rate. The Court also noted that petitioner, as the patent holder, has access to the books of the licensee and could demand an increase in royalty if profits justified it. On the issue of the Director's authority to declare the resolution immediately executory: The Court found this argument untenable. Awards, orders, or decisions of the Patent Office are immediately executory, as provided by Section 4, Rule 44 of the Rules of Court, which states that an appeal does not stay such decisions. Furthermore, the resolution was issued after the parties failed to agree on a licensing agreement, leaving the terms to the Director's discretion. Allowing such resolutions to be subject to further litigation would render the compulsory licensing agreement nugatory.
Main Doctrine
The Director of Patents, in fixing the royalty rate for a compulsory license, may consider prevailing rates in other countries and the relative size and capacity of the local industry, aiming for a reasonable compromise, and such findings of fact will not be interfered with by courts absent grave abuse of discretion or lack of substantial evidence.